CAMBRIDGE, MA, Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, announced the completion of a multifold oversubscribed $157 million Series C financing round.  
Read More